NGS Sequencing
Tumor tissue samples (self-blood negative control) of pan-cancer were
subjected to NGS for detection the IDH1/2 mutation with 800×
sequencing depth in a College of American Pathologists (CAP) and
Clinical Laboratory Improvement Amendments (CLIA) certified laboratory
of 3D Medicines Inc. All pathologic or likely pathologic mutations ofIDH1/IDH2 were considered. In addition, the TMB was defined as
the total number of nonsynonymous mutation in coding region. This study
was conducted under the approval of the ethics committees of the
hospitals and informed consents were obtained from patients.